Endothelial Progenitor Cells and Pulmonary Idiopathic Arterial Hypertension

The Determination of Endothelial Progenitor Cells in Pulmonary Idiopathic Arterial Hypertension.

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00551408

Enrollment

Registered

2007-10-31

Start date

2007-08-31

Completion date

2016-10-31

Last updated

2018-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary Idiopathic Arterial Hypertension

Brief summary

Endothelial dysfunction ultimately represents an imbalance between the magnitude of injury and the capacity for repair. Current evidence established that endothelial progenitor cells (EPC) participate in several models of vascular disease as acute coronary syndromes, stroke, diabetes, peripheral artery disease, etc. However EPC in the setting of PAH is less well established. The target of this study is to demonstrate if the number of EPC is increased in a mexican population of patients with PAH.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

* Patients were included in the study if they were in The WHO functional class II to III, and had a mean pulmonary artery pressure \>30 mm Hg on right heart catheterization. The ability to walk \>50 m during a standardized 6-min walk test.

Exclusion criteria

* Pulmonary hypertension as a result of heart disease, pulmonary disease, sleep-associated disorders, chronic thromboembolic disease, autoimmune or collagen vascular disease, HIV infection, liver disease, major bleeding requiring blood transfusion,renal dysfunction, and evidence for malignant diseases were excluded.

Countries

Mexico

Outcome results